Insulin-like growth factor 1 (IGF1) is an important biomarker for the management of growth hormone disorders. Recently there has been rising interest in deploying mass spectrometric (MS) methods of detection for measuring IGF1. However, widespread clinical adoption of any MS-based IGF1 assay will require increased throughput and speed to justify the costs of analyses, and robust industrial platforms that are reproducible across laboratories.
Download count: 0
- Digital object identifier: 10.1371/journal.pone.0092801
- Identifier TypeInternational standard serial numberIdentifier Value1045-3830
- Identifier TypeInternational standard serial numberIdentifier Value1939-1560
- The article is published at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092801, opens in a new window
Citation and reuse
Cite this item
This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.
Oran, P. E., Trenchevska, O., Nedelkov, D., Borges, C. R., Schaab, M. R., Rehder, D. S., . . . Nelson, R. W. (2014). Parallel Workflow for High-Throughput (>1,000 Samples/Day) Quantitative Analysis of Human Insulin-Like Growth Factor 1 Using Mass Spectrometric Immunoassay. PLoS ONE, 9(3). doi:10.1371/journal.pone.0092801